Original Article
Efficacy of 0.03% Dermatological Tacrolimus Ointment for
Refractory Vernal Keratoconjunctivitis
Hafiza Sadia Imtiaz, Irfan Qayyum Malik, Usama Iqbal, Farhan Ali,
Muhammad Sharjeel
DOI 10.36351/pjo.v35i4.872 Pak J Ophthalmol 2019, Vol. 35, No. 4
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See end of article for authors affiliations …..……………………….. Correspondence to: Dr. Hafiza Sadia Imtiaz Department of Ophthalmology, DHQ-UTH, Gujranwala Email: sadiaimtiaz69@gmail.com |
Purpose: To determine the efficacy of 0.03%
dermatological tacrolimus ointment in patients with refractory vernal
keratoconjunctivitis. Study Design: Quasi-experimental study. Place and Duration of Study: Eye Department, DHQ-Teaching Hospital,
Gujranwala, Pakistan from April 2018 to March 2019. Material and Methods: After approval from hospital ethical
committee and obtaining written informed consent from each patient/guardian,
patients of either gender between 4-16 years of age with VKC not responding
to conventional treatment for more than 8 weeks or having steroid-induced
complications were included in this study. Dermatological
tacrolimus ointment 0.03% was placed in inferior fornix in BD dose frequency
along with topical lubricants. Patients were followed up on a regular
schedule. Individual symptoms score was assessed from the questionnaire and
signs score from observer’s clinical assessment. Data were analyzed using SPSS v23.0. P-value <0.05 was considered as
statistically significant. Results: Forty eyes of 20 patients were
included in this study. Out of 40, four (20%) were female and 16 were male
(80%). Mean baseline score for clinical symptoms was 6.65 ± 1.81 that reduced
to 1.65 ± 0.81 after 12 weeks’ treatment course of tacrolimus with a
significant p-value of 0.006 (p < 0.05). Mean baseline score for clinical
signs was 5.9 ± 1.59 that improved to 1.80 ± 0.83 after 12 weeks’ treatment
course with a statistically significant p-value of 0.003 (p < 0.05). Conclusion: In conclusion, topical tacrolimus
dermatological ointment 0.03% is highly effective in refractory VKC and can
be safely used as an alternative in VKC patients who are steroid-responders. Key
Words: Tacrolimus, Vernal
keratoconjunctivitis, mast cell stabilizers, antihistamines. |
Vernal keratoconjunctivitis (VKC) is a chronic, recurrent,
bilateral conjunctival inflammation that has seasonal exacerbations in summer
and late spring and involve both type I as well as type IV hypersensitivity
reactions1. It mainly affects children between 3 and 16 years of age
with remission by late teens in 95% of cases. Young boys in dry and hot
climates are generally affected2. Patients with VKC suffer from
significant morbidity. Symptoms include severe itching, foreign body sensation,
mucoid discharge, photophobia, and blurred vision. Common clinical signs of VKC
are conjunctival hyperemia, papillary hypertrophy, mucous discharge,
Horner-trantas dots, and corneal involvement3.
Treatment
options available for Vernal keratoconjunctivitis include topical
antihistamines, mast cell stabilizers, NSAIDS, steroids, and immunomodulators4.
Prolonged treatment course with multiple remissions is the major threat faced
among VKC patients. Secondly, as topical steroids are the mainstay of
management for moderate to severe VKC but their injudicious and prolonged use
can lead to secondary glaucoma, cataract, and secondary infections5.
Risk of these complications is particularly high among children who are the
most commonly affected age group in VKC.
To
prevent the occurrence of steroid-induced complications in VKC patients,
certain immunomodulators are in use.6 Two being cyclosporine and
tacrolimus, of which tacrolimus is strong, nonsteroidal, macrolide
immunomodulator isolated from Streptomyces tsukubaensis that has 100 times more potency than cyclosporine7.
Though uncertainty exists about its mechanism of action but it is known to
interact with 12-kDa FK506-binding protein in T-cells and thus inhibits
calcineurin activity that ultimately leads to reduced de-phosphorylation of the
nuclear factor of activated T-cells and hence TH1 (IL-2, interferon-
γ), as well as TH2 cytokines (IL-4, IL-5) production is reduced8.
Tacrolimus is also known to inhibit histamine release from mast cells thus
alleviating the symptom of itching9.
In ophthalmic practice, topical tacrolimus in
doses of 0.001–0.1% are in use for many refractory inflammatory ocular surface
diseases including vernal keratoconjunctivitis (VKC)10. Its proper dosage,
frequency, duration and adverse events in the eye still lie in an undiscovered
domain.
The rationale of this study was to confirm efficacy and safety of low
dose topical tacrolimus ointment 0.03% for refractory vernal
keratoconjunctivitis non-responding to conventional treatment and also to find
out an alternative treatment for VKC eyes suffering from steroid-induced
complications.
MATERIAL
AND METHODS
After approval from the hospital ethical committee,
a written informed consent with demographic variables was collected from
patients/guardians. Patients of either gender between 4-16 years of age with
VKC not responding to conventional treatment (anti-histamines/mast cell stabilizers/NSAIDS/steroids) for more than 8 weeks or having steroid-induced
complications were included in this study. Exclusion criteria was immunocompromised
patients, pregnant females, recent ocular surgery in previous 3 months and infectious
ocular disease in particular, herpes infection. This study included 40 eyes of
20 patients and was conducted at eye department of DHQ-Teaching Hospital
Gujranwala during 12 months (April 2018 – March 2019).
All
patients underwent routine ophthalmic examination including Visual acuity, BCVA,
Slit lamp Biomicroscopy with Fluorescein staining as well as photography,
Fundus evaluation, and Applanation Tonometry. Diagnosis of VKC was made on a clinical
basis with 4 symptoms of itching, redness, photophobia, mucoid discharge and 4
clinical signs of conjunctival hyperemia, papillary hypertrophy, Horner-Trantas
dots, and corneal involvement.
Before starting treatment with tacrolimus and at each visit
thereafter, all patients/guardians were given a questionnaire to grade all four
symptoms into scale 0 (none), scale 1 or mild, scale 2 or moderate, and scale 3
or severe11. Similarly, clinical signs were also categorized by one
observer into scale 0 (none), scale 1 (mild), scale 2 (moderate), or scale 3
(severe) in following way11.
Table 1: Signs score grading.
Signs |
Score |
Description |
Conjunctival Hyperemia |
3 2 1 0 |
Diffuse dilated vessels over entire bulbar conjunctiva Dilatation of many vessels Dilatation of few vessels None |
Papillae |
3 2 1 0 |
Papillae size > 0.3 mm Papillae size 0.2-0.3mm Papillae size <0.2mm None |
Trantas |
3 2 1 0 |
> 6 dots 4-6 dots 1-3 dots None |
SPK |
3 2 1 0 |
Total corneal surface More than half corneal surface Less than half corneal surface None |
Dermatological
Tacrolimus ointment 0.03% was advised to be placed in inferior fornix in BD dose
while all other conventional topical medications (anti-histamine, mast cell
stabilizers, NSAIDS) were discontinued except for steroids that were tapered
off. Topical lubricants were also prescribed in BD frequency to reduce
irritation, which is seldom observed with tacrolimus ointment.
Patients were followed up at 3 days
after starting the medication and then at 2 weeks, 4 weeks, 8 weeks and final
follow up at 3 months. In each visit, the above mentioned questionnaire and
ophthalmic examination were repeated to attain final clinical score along with
photographs and the patients were also specifically asked about the discomfort
associated with the use of tacrolimus ointment.
Improvement of each
symptom or sign was defined as at least 1-score reduction in severity compared
with values before the treatment. Paired t-test was used to statistically analyze
the changes in mean clinical score before and after treatment. Data was analyzed using SPSS v23.0. Results
were expressed as Mean ± SD and percentages. P-values of 0.05 or less
were considered as statistically significant.
RESULTS
Average age of the participants of the study was 9.05
± 3.58 (range 4-16) years. Eleven (55%) patients were between 4-8 years of age,
5 (25%) between 9-12 years of age and 4 (20%) between 13-16 years of age.
Mean duration of
conventional treatment before starting tacrolimus ointment was 10 months with
SD of ± 5.96. While using conventional treatment, 4 patients (20%) were only on
topical steroids, 9 patients (45%) were using anti-histamines, mast cell
stabilizers and NSAIDS and 7 (35%) were on combination of all.
Most common symptom found in this study
was itching that was present in 90% of total study population and it also first
responded to treatment within 2 weeks. Least common symptom observed was
photophobia that was present in 40% of cases.
Most common sign observed in this study
was papillary hypertrophy that was present in 80% of total study population and
it slowly responded to treatment within 8 weeks’ duration. Least common sign
observed was corneal involvement that was present in 30% of cases.
Symptoms sore was calculated from questionnaire. Each symptom (total 4)
was graded on a scale of 0-3 thus rendering individual symptoms score out of
12. Mean symptoms score at baseline was 6.65 ± 1.81 that reduced to 6.25 ± 1.68
after three days post-treatment with insignificant p- value of 0.354. At 4
weeks follow up, p-value turned out statistically significant (p = 0.009) with
symptoms score of 3.30 ±
Table 2: Individual
symptoms and signs in percentages.
Symptoms / Signs |
Percentage (%) |
Total No. (n) |
Itching |
90% |
36 eyes of 18 pts. |
Redness |
70% |
28 eyes of 14 pts. |
Mucoid
Discharge |
50% |
20 eyes of 10 pts. |
Photophobia |
40% |
16 eyes of 8 pts. |
Papillary Hypertrophy |
80% |
32 eyes of 16 pts. |
Conjunctival Hyperemia |
70% |
28 eyes of 14 pts. |
Trantas Dots |
40% |
16 eyes of 8 pts. |
Corneal involvement (SPK) |
30% |
12 eyes of 6 pts. |
Table 3: Symptoms score at
different intervals.
Symptoms
Score at Different Intervals |
Mean |
Std. Deviation |
p-value |
Symptoms
score at baseline |
6.65 |
1.81 |
|
Symptoms
score after 3 days |
6.25 |
1.68 |
0.354 |
Symptoms
score after 2 weeks |
4.45 |
1.23 |
|
Symptoms
score after 4 weeks |
3.30 |
1.17 |
0.009 |
Symptoms
score after 8 weeks |
2.45 |
1.19 |
|
Symptoms
score after 12 weeks |
1.65 |
0.81 |
0.006 |
Table 4: Signs score at
different intervals.
Signs
Score at Different Intervals |
Mean |
Std. Deviation |
p-value |
Signs
score at baseline |
5.90 |
1.59 |
|
Signs
score after 3 days |
5.45 |
1.36 |
0.233 |
Signs
score after 2 weeks |
4.10 |
1.07 |
|
Signs
score after 4 weeks |
3.30 |
1.08 |
0.035 |
Signs
score after 8 weeks |
2.60 |
1.05 |
|
Signs
score after 12 weeks |
1.80 |
0.83 |
0.003 |
1.17 that markedly reduced to 1.65 ±
0.81 with significant p-value of 0.006.
Signs
score was calculated from observer’s clinical response at each visit in which
each clinical sign (total 4) was graded by observer on a scale of 0-3, again
rendering the total score of 12. Mean signs score at baseline was 5.90 ± 1.59
that reduced to 5.45 ± 1.38 three days post-treatment with insignificant
p-value of 0.233. At 4 weeks follow up, p-value turned out statistically
significant (p = 0.035) with signs score of 3.30 ± 1.08 that markedly reduced
to 1.80 ± 0.83 with significant p-value of 0.003.
At baseline, mean score for
symptoms was 6.65 while that for
Fig. 1: Line
Chart showing Gradual Decline in Symptoms and Signs Score.
2A): Grade III Papillary
Hypertrophy at Baseline.
2B): Grade I Papillary Hypertrophy at
4 Weeks.
2C): Grade 0 Papillary Hypertrophy at
8 Weeks Duration.
Fig. 2(A-C): Resolution
of Papillary Hypertrophy with Tacrolimus.
3A): Grade III Trantas Dots at
baseline.
3B): Grade I Trantas Dots at 8
weeks duration
Fig. 3(A-B): Resolution of Limbal Trantas Dots with Tacrolimus.
signs was 5.90. At 4 weeks interval both mean scores were found to be
3.30. While after 4 weeks, symptoms score reduced more markedly than signs
score and at final follow up, mean score for symptoms was 1.65 and that for
signs was 1.80.
DISCUSSION
This study confirmed the efficacy and safety of
topical tacrolimus 0.03% in VKC, which were refractory to conventional
treatment. All patients showed marked improvement in signs and symptoms without
developing any significant adverse effects. Mild irritation was noted in 4
patients initially with the use of tacrolimus ointment but that subsided after
one week. Chatterjee et al. also reported mild transient stinging sensation in
their study population but that also lasted only for few days12.
Most common symptom in our study was itching that
was noted in 90% (36 eyes of 18 patients) of patients and it was also first to
resolve within 2 weeks duration. In a similar study by Al-Amri et al 17 out of 20 patients complained of itching
and all cases improved within 1 week13.
Most common clinical sign noted was papillary hypertrophy
that was present in 80% of patients (32 eyes of 16 subjects) and it resolved in
relatively longer period of about 8 weeks. Conjunctival hyperemia responded to
treatment first and resolved within 4 weeks in 12 out of 20 patients. Barot et
al. also reported conjunctival hyperemia to get resolved within 1 month in 60%
of patients.14 Corneal involvement was least observed among
participant patients probably due to early visit to Ophthalmologist.
In our study, Mean baseline score for clinical
symptoms was 6.65 ± 1.81 that reduced to 1.65 ± 0.81 after 12 weeks treatment
course of topical tacrolimus with significant p-value of 0.006 (p < 0.05). Mean
baseline score for clinical signs was 5.9 ± 1.59 that improved to 1.80 ± 0.83
after 12 weeks treatment course with statistically significant p-value of 0.003
(p < 0.05). Results of this study are also supported by few other recently
conducted studies15,16,17. Fukushima et al. carried out similar
study on large population including 1436 patients with refractory allergic
conjunctivitis and concluded that 0.1% tacrolimus eye drops are highly
effective in treating this refractory condition with corneal involvement thus
alleviating need for topical steroids use.15 Muller et al. suggested
topical tacrolimus 0.03% as sole therapy in VKC by dividing study population in
two groups; One with only topical tacrolimus ointment and other with topical
tacrolimus ointment + olopatadine eye drops and found out same efficacy with no
significant difference between the two groups16. Kheirkhah et al. used low dose 0.005% topical
tacrolimus drops in refractory VKC cases and results showed it effective and
safe alternative for steroid resistant cases17.
Tacrolimus is widely used in many refractory
ophthalmic conditions other than vernal keratoconjunctivitis. Al-Amri reported
the successful use of 0.1% dermatological tacrolimus ointment in 22 patients
with Atopic kertoconjunctivitis18. Many studies have concluded the
therapeutic efficacy of tacrolimus ointment in chronic ocular graft versus host
disease (GVHD)19,20,21. Choi et al. reported the effective role of
0.03% tacrolimus eye drops in refractory dry eye disease associated with
chronic ocular GVHD21.
The limitation of our study is the
off-label use of drug, as its ophthalmic preparation is not available in
Pakistan. But many other authors also safely recommended the use of this skin
preparation for ophthalmic usage18,22. Second limitation of this
study is relatively small sample size and that is due to patient’s/guardian’s
reluctance towards use of off-label drug. Third being short duration of follow
up (3 months) as it cannot be determined the risk of recurrence after drug has
been stopped. In the end, the author suggests that its ophthalmic preparation
should be available in our country like elsewhere so similar studies can be
carried out on large scale for a long period of time for better determination
of its efficacy and safety.
CONCLUSION
In conclusion, topical tacrolimus dermatological
ointment 0.03% is effective in relieving signs and symptoms of refractory VKC
cases that are not responding to conventional treatment and also that topical
tacrolimus can be safely used as an alternative in VKC patients who are
steroid-responders, to lower the risk of steroid-induced complications.
CONFLICT
OF INTEREST
The author has no financial or personnel
conflict of interest in this study.
SOURCE
OF FUNDING
No source of funding in this study.
REFERENCES
1.
Addis H, Jeng B.
Vernal keratoconjunctivitis. Clin Ophthalmol. 2018; 12: 119-23.
2.
Nebbioso M, Zicari A, Celani C, Lollobrigida V, Grenga R, Duse M. Pathogenesis of vernal keratoconjunctivitis and associated factors.
Semin Ophthalmol. 2014; 30 (5-6): 340-4.
3.
Dahal P, Bhattarai S.
Clinical presentation of vernal keratoconjunctivitis in Bharatpur Medical
College. J Coll Med Sci-Nepal. 2015; 11 (2): 17-9.
4.
Nagrale D.
Study of clinical features and management of vernal keratoconjunctivitis. J Med
Sci Clini Res. 2017; 05 (01): 15754-9.
5.
Phulke S, Kaushik S, Kaur S, Pandav S. Steroid-induced glaucoma: An avoidable irreversible blindness. J
Curr Glaucoma Pract. 2017; 11 (2): 67-72.
6.
Sacchetti M, Bruscolini A, Abicca I, Nebbioso M, La Cava M, Bonini
S et al. Current and emerging
treatment options for vernal keratoconjunctivitis. Expert Opin Orphan Drugs,
2017; 5 (4): 343-53.
7.
Singla E, Singh H, Kaur, Walia S. A double-masked comparison of 0.1% tacrolimus ointment and 2%
cyclosporine eye drops as first line drugs in the treatment of vernal keratoconjunctivitis.
IOSR J Dent Med Sci. 2017; 16 (6): 30-5.
8.
Müller G, José N, Castro R, Holanda E. Long-term use of topical tacrolimus ointment: a safe and
effective option for the treatment of vernal keratoconjunctivitis. Arq Bras
Oftalmol. 2019; 82 (2): 119-23.
9.
Liendo V, Vola M, Barreiro T, Wakamatsu T, Gomes J, Santos M. Topical tacrolimus for the treatment of severe allergic
keratoconjunctivitis in children. Arq Bras Oftalmol. 2017; 80 (4): 211-4.
10.
Shoughy S, Jaroudi M, Tabbara K. Efficacy and safety of low-dose topical tacrolimus in vernal
keratoconjunctivitis. Clin Ophthalmol. 2016; 10: 643-7.
11.
Al-Amri A, Fiorentini S, Albarry M, Bamahfouz A. Long-term use of 0.003% tacrolimus suspension for treatment of
vernal keratoconjunctivitis. Oman J Ophthalmol. 2017; 10 (3): 145-9.
12.
Chatterjee S, Agrawal D. Tacrolimus in corticosteroid- refractory vernal keratoconjunctivitis.
Cornea. 2016; 35 (11): 1444-8.
13.
Al-Amri A, Mirza A, Al-Hakami A. Tacrolimus ointment for treatment of vernal keratoconjunctivitis.
Middle East Afr J Ophthalmol. 2016; 23 (1): 135-8.
14.
Barot R, Shitole S, Bhagat N, Patil D, Sawant P, Patil K. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic
ocular diseases. J Clin Diagn Res. 2016; 10 (6): NC05-9.
15.
Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N,
et al. Therapeutic effects of
0.1% tacrolimus eye drops for refractory allergic ocular diseases with
proliferative lesion or corneal involvement. Br J Ophthalmol. 2014; 98 (8): 1023-7.
16.
Müller G, José N, de Castro R. Topical Tacrolimus 0.03% as sole therapy in vernal
keratoconjunctivitis. Eye Contact Lens: Sci Clin Pract. 2014; 40 (2): 79-83.
17.
Kheirkhah A, Zavareh M, Farzbod F, Mahbod M, Behrouz M. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.
Eye, 2011; 25 (7): 872-80.
18.
Al-Amri A.
Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.
Am J Ophthalmol. 2014; 157 (2): 280-6.
19.
Jung J, Lee Y, Yoon S, Kim T, Kim E, Seo K. Long-term result of maintenance treatment with tacrolimus
ointment in chronic ocular graft-versus-host disease. Am J Ophthalmol. 2015; 159
(3): 519-27.
20.
Ryu E, Kim J, Laddha P, Chung E, Chung T. Therapeutic effect of 0.03% tacrolimus ointment for ocular graft
versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol. 2012;
26 (4):241-7.
21.
Choi S, Chung S.
Therapeutic effects of 0.03% tacrolimus eye drops for chronic ocular
graft-versus-host disease. J Korean Ophthalmol Soc. 2015; 56 (10): 1505-10.
22.
Liu F, Liu H, Chu H, Chen W, Hu F, Wang I. Dermatologic tacrolimus ointment on the eyelids for
steroid-refractory vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol.
2019; 257 (5): 967-74.
Author’s Affiliation
Dr. Hafiza Sadia Imtiaz
Postgraduate trainee
Department of Ophthalmology
DHQ-UTH, Gujranwala
Dr. Irfan Qayyum Malik
Associate professor
Department of Ophthalmology
DHQ-UTH, Gujranwala
Dr. Usama Iqbal
Postgraduate trainee
Department of Ophthalmology
DHQ-UTH, Gujranwala
Dr. Farhan Ali
Assistant professor
Department of Ophthalmology
DHQ-UTH, Gujranwala
Dr. Muhammad Sharjeel
Senior registrar
Gomal medical college
Dera Ismail Khan
Author’s
Contribution
Dr.
Hafiza Sadia Imtiaz
Manuscript
writing, Data collection and analysis
Dr. Irfan Qayyum Malik
Supervisor, Manuscript review
Dr. Usama Iqbal
Data collection, Manuscript writing
Dr. Farhan Ali
Data analysis, Manuscript writing
Dr. Muhammad Sharjeel
Manuscript writing